Lipid Sciences meets final FDA condition for human trial of PDS-2

By Lisa Kerner

Erie, Pa., April 20 - Lipid Sciences, Inc. said it received notification from the Institutional Review Board of MedStar Research Institute approving a human clinical trial of the company's Plasma Delipidation System-2 (PDS-2).

With this approval, all of the conditions set forth by the Food and Drug Administration have been met to begin the trial, according to a form 8-K filing.

Lipid Sciences is a development-stage biotechnology company located in Pleasanton, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.